Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peyman Hadji

Showing results (91-100 of 171) with videos related to

Pageof 18
Sort By:
Joint Bone Spine|December 11, 2007
Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: A randomized, crossover study (BALTO II)Peyman Hadji, Helmut Minne, Michael Pfeifer, et al.
Journal of Bone Oncology|February 25, 2016
Zoledronic acid and atorvastatin inhibit αvβ3-mediated adhesion of breast cancer cellsMaria Wilke, Andy Göbel, Martina Rauner, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|May 5, 2011
Once-yearly zoledronic acid and days of disability, bed rest, and back pain: randomized, controlled HORIZON Pivotal Fracture TrialJane A Cauley, Dennis Black, Steven Boonen, et al.
European Journal of Clinical Investigation|May 20, 2014
Serum and urinary NGAL but not KIM-1 raises in human postrenal AKIAnja Urbschat, Stefan Gauer, Patrick Paulus, et al.
Breast Cancer Research : BCR|August 11, 2017
Concurrent antitumor and bone-protective effects of everolimus in osteotropic breast cancerAndrew J Browne, Marie L Kubasch, Andy Göbel, et al.
The Oncologist|June 3, 2008
Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozoleAdam Brufsky, Nigel Bundred, Robert Coleman, et al.
Archives of Osteoporosis|January 22, 2022
Prevalence of FRAX risk factors and the osteoporosis treatment gap among women ≥ 70 years of age in routine primary care across 8 countries in EuropeEugene McCloskey, Jeetandera Rathi, Stephane Heijmans, et al.
BJOG : an International Journal of Obstetrics and Gynaecology|March 8, 2023
The risk of thromboembolism and use of combined oral contraceptives: a commentMartin Birkhäuser, Bettina Böttcher, Ariane Germeyer, et al.
Journal of Bone Oncology|February 25, 2016
The ZOTECT study: Effect of zoledronic acid on bone metabolism in patients with bone metastases from prostate or breast cancerPeyman Hadji, May Ziller, Tobias Maurer, et al.
Breast Care (Basel, Switzerland)|August 11, 2020
Assessment of Quality of Life in Postmenopausal Women with Early Breast Cancer Participating in the PACT Trial: The Impact of Additional Patient Information Material Packages and Patient ComplianceChristian Jackisch, Rolf Kreienberg, Maria Blettner, et al.
Pageof 18

Showing results (91-100 of 171) with videos related to

Sort By:
Pageof 18
Joint Bone Spine|December 11, 2007
Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: A randomized, crossover study (BALTO II)Peyman Hadji, Helmut Minne, Michael Pfeifer, et al.
Journal of Bone Oncology|February 25, 2016
Zoledronic acid and atorvastatin inhibit αvβ3-mediated adhesion of breast cancer cellsMaria Wilke, Andy Göbel, Martina Rauner, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|May 5, 2011
Once-yearly zoledronic acid and days of disability, bed rest, and back pain: randomized, controlled HORIZON Pivotal Fracture TrialJane A Cauley, Dennis Black, Steven Boonen, et al.
European Journal of Clinical Investigation|May 20, 2014
Serum and urinary NGAL but not KIM-1 raises in human postrenal AKIAnja Urbschat, Stefan Gauer, Patrick Paulus, et al.
Breast Cancer Research : BCR|August 11, 2017
Concurrent antitumor and bone-protective effects of everolimus in osteotropic breast cancerAndrew J Browne, Marie L Kubasch, Andy Göbel, et al.
The Oncologist|June 3, 2008
Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozoleAdam Brufsky, Nigel Bundred, Robert Coleman, et al.
Archives of Osteoporosis|January 22, 2022
Prevalence of FRAX risk factors and the osteoporosis treatment gap among women ≥ 70 years of age in routine primary care across 8 countries in EuropeEugene McCloskey, Jeetandera Rathi, Stephane Heijmans, et al.
BJOG : an International Journal of Obstetrics and Gynaecology|March 8, 2023
The risk of thromboembolism and use of combined oral contraceptives: a commentMartin Birkhäuser, Bettina Böttcher, Ariane Germeyer, et al.
Journal of Bone Oncology|February 25, 2016
The ZOTECT study: Effect of zoledronic acid on bone metabolism in patients with bone metastases from prostate or breast cancerPeyman Hadji, May Ziller, Tobias Maurer, et al.
Breast Care (Basel, Switzerland)|August 11, 2020
Assessment of Quality of Life in Postmenopausal Women with Early Breast Cancer Participating in the PACT Trial: The Impact of Additional Patient Information Material Packages and Patient ComplianceChristian Jackisch, Rolf Kreienberg, Maria Blettner, et al.
Pageof 18